Evidence mapPaperPMID 42432268Full record

ReviewProtoplasma2026

Triple identity of medicinal plant-derived extracellular vesicles.

Yingping Wang, Jin Ke, Jinlian Yang, Lili Cui, Yunshu Ma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Protoplasma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yingping WangYunnan Key Laboratory of Dai and Yi Medicines, College of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, China.
Jin KeYunnan Key Laboratory of Dai and Yi Medicines, College of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, China.
Jinlian YangYunnan Key Laboratory of Dai and Yi Medicines, College of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, China.
Lili CuiYunnan Key Laboratory of Dai and Yi Medicines, College of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, China. cuilili1015@163.com.
Yunshu MaYunnan Key Laboratory of Dai and Yi Medicines, College of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, China. yunshuma2@126.com.

Funding

Major science and technology Special Program of Science and Technology Department of Yunnan Province 202302AA310031Scientific Research Foundation of Education Department of Yunnan Province 2024J0518Social development special projects-Key research and development plan of Science and Technology Department of Yunnan Province 202303AC100025
6 · The paper itself

Abstract

Medicinal plant-derived extracellular vesicles (MPDEVs) are nanoscale vesicles secreted by medicinal plant cells. They are enriched in diverse functional components and function as natural mediators that facilitate intercellular communication and regulate multiple physiological processes. Owing to their unique biological activities and delivery capabilities, these vesicles have emerged as a frontier research hotspot. Recent studies have demonstrated that MPDEVs exhibit excellent biocompatibility and cross-species delivery potential and can be engineered to encapsulate small-molecule compounds for use as drug delivery vectors. Remarkably, MPDEVs also display notable intrinsic therapeutic effects and can be directly applied as natural therapeutic agents in various disease models. Furthermore, MPDEVs can be co-administered with conventional therapeutic drugs to strengthen their efficacy and improve bioavailability. This article systematically summarizes the biogenesis, composition, and functional properties of MPDEVs and emphasizes their broad application potential, characterized by a triple identity as intelligent carriers, natural therapeutic agents, and synergistic treatment systems. Nonetheless, the translation of MPDEVs from laboratory research to clinical application is impeded by several critical challenges, including source heterogeneity, the absence of specific biomarkers for efficient purification and identification, and a lack of standardized quality control procedures. Accordingly, this paper also highlights these core limitations and outlines future development directions aimed at facilitating clinical translation and industrial deployment. The objective is to provide a comprehensive reference and theoretical framework to support overcoming these constraints and to contribute to the advancement of MPDEVs into reliable and scalable biomedical tools.

Indexed as

Combination therapyDrug deliveryIntrinsic activityMedicinal plant-derived extracellular vesiclesNano-drug carriers

Identifiers

PMID42432268

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.